<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04587271</url>
  </required_header>
  <id_info>
    <org_study_id>58219</org_study_id>
    <secondary_id>K01TW009987-06</secondary_id>
    <nct_id>NCT04587271</nct_id>
  </id_info>
  <brief_title>Nutritional Impact of Moringa Oleifera Leaf Supplementation in Mothers and Children</brief_title>
  <official_title>Investigating the Impact of Moringa Oleifera Leaf Supplementation on Growth, Nutrition, Lactation, and Inflammation in Kenyan Breastfeeding Mothers and Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Suzanna L Attia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fogarty International Center of the National Institute of Health</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Kentucky</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Studies to date on the effects of Moringa oleifera in diabetes and anemia and animal studies&#xD;
      that examine the utility of moringa for increased milk and litter yield are of small scale,&#xD;
      however high-quality large-scale placebo or case-controlled clinical trials to define the&#xD;
      impact on infants of moringa leaf powder consumption by breastfeeding mothers are lacking.&#xD;
      Moringa has a traditional and agricultural history of use as a galactagogue; despite this and&#xD;
      its incorporation into products such as Mother's Milk Tea© and placement on NIH LactMed&#xD;
      Lactation Database, this property has not been studied in large clinical trials nor in&#xD;
      populations dependent on breastmilk such as in Kisumu, Kenya. This study will improve and add&#xD;
      to existing knowledge of moringa's effect on human breastmilk and will provide novel&#xD;
      information on the effect of moringa supplementation to lactating mothers on their infant's&#xD;
      intestinal inflammation and health. Further understanding of the acceptability of moringa&#xD;
      leaf in a staple food of porridge and more the effect of moringa supplementation on infant&#xD;
      and childhood growth, nutrition, and intestinal and systemic inflammation may translate in&#xD;
      the future to the cultivation of moringa at the community or household level as an effective&#xD;
      resource for the improvement of childhood undernutrition.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 21, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Body Weight</measure>
    <time_frame>3 months</time_frame>
    <description>Body weight will be measured at baseline and monthly to 3 months.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Height</measure>
    <time_frame>3 months</time_frame>
    <description>Height (body length) will be measured at baseline and monthly to 3 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Mid-Upper Arm Circumference</measure>
    <time_frame>3 months</time_frame>
    <description>Mid-upper arm circumference (MUAC) will be measured at baseline and monthly to 3 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Head Circumference</measure>
    <time_frame>3 months</time_frame>
    <description>Head circumference will be measured at baseline and monthly to 3 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Vitamin A</measure>
    <time_frame>3 months</time_frame>
    <description>Serum retinol binding protein will be used to survey vitamin A levels in infants at baseline and monthly to 3 months..</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in CRP Levels</measure>
    <time_frame>3 months.</time_frame>
    <description>C-reactive protein (CRP) will be used to measure inflammation at baseline and monthly to 3 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the Soluble Transferrin-Ferritin Index</measure>
    <time_frame>3 months.</time_frame>
    <description>The soluble transferrin receptor-transferrin index (sTfR-F) will be used to evaluate anemia at baseline and monthly to 3 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Fecal Neopterin</measure>
    <time_frame>3 months</time_frame>
    <description>Fecal neopterin will be measured at baseline and monthly to 3 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Fecal Myeloperoxidase</measure>
    <time_frame>3 months</time_frame>
    <description>Fecal myeloperoxidase will be measured at baseline and monthly to 3 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Alpha-1-Antitrypsin</measure>
    <time_frame>3 months</time_frame>
    <description>Fecal alpha-1-antitrypsin will be measured at baseline and monthly to 3 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence of Diarrhea</measure>
    <time_frame>3 months</time_frame>
    <description>Proportion of participants experiencing diarrhea (&gt; 3 watery stools in 24 hours).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Breastmilk Volume</measure>
    <time_frame>1 day (at 3 months following the intervention)</time_frame>
    <description>Breastmilk volume will be assessed from 24 hour breast pumping or hand expression or weighing the infant before and after feeding for 24 hours.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Breastmilk Vitamin A</measure>
    <time_frame>1 day (at 3 months following the intervention)</time_frame>
    <description>Levels of vitamin A in breastmilk will be measured at the end of the study. hours.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Breastmilk Retinol</measure>
    <time_frame>1 day (at 3 months following the intervention)</time_frame>
    <description>Levels of retinol in breastmilk will be measured at the end of the study. hours.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Breastmilk Vitamin E</measure>
    <time_frame>1 day (at 3 months following the intervention)</time_frame>
    <description>Levels of vitamin E in breastmilk will be measured at the end of the study. hours.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Breastmilk Catalase</measure>
    <time_frame>1 day (at 3 months following the intervention)</time_frame>
    <description>Levels of catalase in breastmilk will be measured at the end of the study. hours.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Breastmilk Lactoferrin</measure>
    <time_frame>1 day (at 3 months following the intervention)</time_frame>
    <description>Levels of lactoferrin in breastmilk will be measured at the end of the study. hours.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Malnutrition</condition>
  <condition>Wasting</condition>
  <condition>Growth Failure</condition>
  <arm_group>
    <arm_group_label>Lactating Mothers (Moringa)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lactating mothers.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Breastfeeding Infants (Moringa)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Breastfeeding infants from lactating mothers</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Children (Moringa)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Children from 6-59 months of age.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lactating Mothers (placebo)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Lactating mothers.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Breastfeeding Infants (placebo)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Breastfeeding infants from lactating mothers</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Children (placebo)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Children from 6-59 months of age.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Moringa oleifera (high dose)</intervention_name>
    <description>Mothers will receive 20 grams of moringa leaf powder in porridge consumed daily for three months.</description>
    <arm_group_label>Breastfeeding Infants (Moringa)</arm_group_label>
    <arm_group_label>Lactating Mothers (Moringa)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Moringa oleifera (low dose)</intervention_name>
    <description>Children will receive 5-10 grams of moringa leaf powder in porridge consumed daily for three months.</description>
    <arm_group_label>Children (Moringa)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Mothers and children will receive porridge with placebo.</description>
    <arm_group_label>Breastfeeding Infants (placebo)</arm_group_label>
    <arm_group_label>Children (placebo)</arm_group_label>
    <arm_group_label>Lactating Mothers (placebo)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  lactating women at least 18 years of age and their exclusively breastfed infants&#xD;
             within 14 days of delivery.&#xD;
&#xD;
          -  children 6-59 months of age who eat food&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  regular maternal consumption of moringa&#xD;
&#xD;
          -  receipt and consumption of food supplementation program&#xD;
&#xD;
          -  inability to feed orally or refusal to eat moringa or placebo porridge&#xD;
&#xD;
          -  for infants, prematurity (&lt;36 weeks gestational age)&#xD;
&#xD;
          -  for infants, significant congenital disease&#xD;
&#xD;
          -  for infants, inability to feed orally&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Kombewa County Hospital</name>
      <address>
        <city>Kisumu</city>
        <zip>40102</zip>
        <country>Kenya</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jerusha Mogaka, BSN, MPH</last_name>
      <phone>254 726 669 264</phone>
      <email>jerunyags@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chulaimbo Sub- County Hospital</name>
      <address>
        <city>Kisumu</city>
        <zip>40105</zip>
        <country>Kenya</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jerusha Mogaka, BSN, MPH</last_name>
      <phone>254 726 669 264</phone>
      <email>jerunyags@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Kenya</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>October 8, 2020</study_first_submitted>
  <study_first_submitted_qc>October 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 14, 2020</study_first_posted>
  <last_update_submitted>September 21, 2021</last_update_submitted>
  <last_update_submitted_qc>September 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Kentucky</investigator_affiliation>
    <investigator_full_name>Suzanna L Attia</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Moringa oleifera</keyword>
  <keyword>supplementation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malnutrition</mesh_term>
    <mesh_term>Failure to Thrive</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

